Adverse Outcomes | Hb < aaHb (n = 152) | Hb ≥ aaHb (n = 444) | P | Hb * SpO2 < aaHb (n = 263) | Hb * SpO2 ≥ aaHb (n = 333) | P |
---|---|---|---|---|---|---|
Death | 1(0.7%) | 1(0.2%) | > 0.999 | 3(1.1%) | 1(0.3%) | 0.326 |
ECMO placement | 1(0.7%) | 2(0.5%) | > 0.999 | 2(0.8%) | 1(0.3%) | 0.586 |
ICU > 30d | 1(0.7%) | 5(1.1%) | > 0.999 | 1(0.4%) | 5(1.5%) | 0.236 |
Extubation failure | 8(5.3%) | 18(4.15%) | 0.498 | 16(6.1%) | 10(3%) | 0.072 |
Thromboembolic events | 2(1.3%) | 6(1.4%) | > 0.999 | 3(1.1%) | 5(1.5%) | > 0.999 |
Significant cardiac disorders | 5(3.3%) | 7(1.6%) | 0.194 | 8(3%) | 4(1.2%) | 0.112 |
Severe renal failure | 3(2%) | 14(3.2%) | 0.58 | 11(4.2%) | 6(1.8%) | 0.09 |
Adverse outcomes | 21(13.8%) | 43(9.7%) | 0.172 | 40(15.2%) | 24(7.2%) | 0.002* |